Autism Spectrum Disorders – ASD

Autism Spectrum Disorders – ASD


τις Διαταραχές Φάσματος του Αυτισμού - ASD - a-s-d-umbrella

Autism Spectrum Disorders – ASD


Autism is a serious neuro-psychological developmental disorder of child’s immature brain. It is extremely complex, determined according to the behavior, and it is characterized by deficient communication and sociability. Stereotypic repeated movements, positions, postures, and words are also observed. Autism is not a disease. It is a Syndrome, with multiple non genetic and genetic causes, which is usually present from childbirth, but not evident before the age of three.

Autism was described for the first time in 1943 by Kanner. This is why it is also referred to as Kanner Syndrome, a subcategory placed at one end of the spectrum. This subcategory is called Autism Spectrum Disorders (A.S.D.). In its other end, Symptoms of Higher Functioning are included, such as Asperger Syndrome, while in the middle other types of autism are included.

Pervasive Developmental Disorders (P.D.D.) are a wider group of disorders. Autism Spectrum Disorders (A.S.D.) constitute one of its subcategories.

Διαταραχές Φάσματος του Αυτισμού - ASD - pdd-asd-diagram

Autism Spectrum Disorders – ASD and Pervasive Developmental Disorders – PDD


Now, when we refer to autism, we actually refer to Autism Spectrum Disorders – ASD. These are characterized by disturbances in three behavioral aspects: social interaction, language and communication, as well as imaginative play and the range of interests and activities.

During the past twenty years, a significant increase of individuals diagnosed with Autism Spectrum Disorders has been observed. This is probably due to increased awareness and the change of diagnostic criteria, as well as to the multiple environmental effects.

The term Syndrome in Medicine is used to describe conditions with unknown causes that are also multifactorial. This is why syndromes are never cured and all treatments are supportive. They mainly help in improving patients’ living conditions.

Many professionals are involved in the treatment of Autism; child psychologists, child therapists, speech therapists, music therapists, child psychiatrists, developmental experts, occupational therapists, educators, psychiatrists, psychologists.

They all together try to treat something with unknown cause. Chaos and great concern for the parents, who rely on the experts for the management of Autism.

However, what we definitely know is that Autism Spectrum Disorders – ASD are due to genetic (gene) hereditary and acquired factors.

One of its main characteristics is the different response of patients to all types of stimuli, either external or internal from the body itself.

Responses to these stimuli are generally biochemically guided and controlled by hormones. They are directly dependent on environmental effects and our response to it (oxidative stress), as well as diet.


Treatment through a simple biochemical means gets closer to the causal treatment of Autism Spectrum Disorders – ASD.

Based on this self-evident approach of the Functional Medicine system, the child or adult with Autism Spectrum Disorder – ASD is treated aiming at restoring or strengthening biochemical and hormonal balance, depending on the aberration that will be identified.

With the gradual increase of energy production at the cellular level, i.e. increasing response to stimuli, we strengthen all metabolic pathways and mechanisms, as well as the production of hormones, so that the individual can be at its optimal physical state and respond maximally to external stimuli.

For Autism Spectrum Disorders – ASD, the essential exams concern the molecular profile for heavy metals, test of toxicosis from organic solvents, and full hormonal profile.

In addition, an exam for the main gene polymorphisms is also performed.

Treatment may also include Molecular nutrition. The duration of treatment, aiming at improving responses at the social, language and communication levels, is from six to twelve months.


Dr. Nikoleta Koini, M.D.

Doctor of Functional, Preventive, Anti-ageing and Restorative Medicine

Diplomate and Board Certified in Anti-aging, Preventive, Functional and Regenerative Medicine from A4M (American Academy in Antiaging Medicine).


  1. Curtis TR, ed. The London Encyclopedia. London: Griffi n and Co; 1839.
  2. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):947-956.
  3. Williams TA, Mars AE, Buyske SG, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med. 2007;161(4):356-361.
  4. Reddy MN. Reference ranges for total homocysteine in children. Clin Chim Acta. 1997;262(1-2):153-155.
  5. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80(6):1611-1617.
  6. Bull G, Shattock P, Whiteley P, et al. Indolyl-3-acryloylglycine (IAG) is a putative diagnostic urinary marker for autism spectrum disorders. Med Sci Monit. 2003;9(10):CR422-CR425.
  7. Wright B, Brzozowski AM, Calvert E, et al. Is the presence of urinary indolyl-3-acryloylglycine associated with autism spectrum disorder? Dev Med Child Neurol. 2005;47(3):190-192.
  8. Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo- controlled pilot study. Biol Psychiatry. 2007;61(4):551-553.
  9. Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry. 2003;64(7):848-849.
  10. Poling JS, Frye RE, Shoffner J, Zimmerman AW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol. 2006;21(2):170-172.
  11. Herbert MR. Autism: A brain disorder or a disorder of the brain? Clin Neuropsychiatry. 2005;2(6):354-379.
  12. Herbert MR. Large brains in autism: the challenge of pervasive abnormality. Neuroscientist. 2005;11(5):417-440.
  13. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57(1):67-81. Erratum in: Ann Neurol. 2005 Feb;57(2):304.
  14. Wakefi eld AJ, Ashwood P, Limb K, Anthony A. The signifi cance of ileo-colonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. Eur J Gastroenterol Hepatol. 2005;17(8):827-836.
  15. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2004;(2):CD003498.
  16. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant infl ammatory bowel disease. Mol Pathol. 2002;55(2):84-90.
  17. Kawashima H, Mori T, Kashiwagi Y, Takekuma K, Hoshika A, Wakefi eld A. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci. 2000;45(4):723-729.
  18. Hornig M, Briese T, Buie T, et al. Lack of association between measles virus vaccine and autism with enteropathy: a case-control study. PLoS ONE. 2008;3(9):e3140.
  19. Bradstreet JJ, El Dahr J, Anthony A, Kartzinel JJ, Wakefi eld AJ. Detection of measles virus genomic RNA in cerebrospinal fl uid of children with regressive autism: a report of three cases. J Am Phys Surgeons. 2004;9(2):38-45.
  20. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet. 1999;353(9169):2026-2029.
  21. Williams R. Biochemical Individuality, New York: McGraw Hill; 1998.
  22. Autism Research Initiative. Treatment Options for Mercury/metal Toxicity in Autism and Related Developmental Disabilities: Consensus Position Paper. San Diego, CA: Autism Research Initiative; 2005. Available at: http://www.autism.com heavymetals.pdf. Accessed September 17, 2008.
  23. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in fi rst baby haircuts of autistic children. Int J Toxicol. 2003;22(4):277-285.
  24. Adams JB, Romdalvik J, Ramanujam VM, Legator MS. Mercury, lead, and zinc in baby teeth of children with autism versus controls. J Toxicol Environ Health A. 2007;70(12):1046-1051.
  25. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357(13):1281-1292.
  26. Geier DA, Geier MR. A prospective study of mercury toxicity biomarkers in autistic spectrum disorders. J Toxicol Environ Health A. 2007;70(20):1723-1730.
  27. Echeverria D, Woods JS, Heyer NJ, et al. The association between a genetic polymorphism of coproporphyrinogen oxidase, dental mercury exposure and neurobehavioral response in humans. Neurotoxicol Teratol. 2006;28(1):39-48
  28. Heyer NJ, Echeverria D, Bittner AC Jr, Farin FM, Garabedian CC, Woods JS. Chronic low-level mercury exposure, BDNF polymorphism, and associations with self-reported symptoms and mood. Toxicol Sci. 2004;81(2):354-363. Epub 2004 Jul 14.
  29. Echeverria D, Woods JS, Heyer NJ, et al. Chronic low-level mercury exposure, BDNF polymorphism, and associations with cognitive and motor function. Neurotoxicol Teratol. 2005;27(6):781-796.